Corporate Presentation

Obesity ZEAL& ZEALAND PHARMA We believe in a shift from maximizing weight loss towards 2000 quality of weight loss and effects on comorbidities... 5% Intensive lifestyle therapy First-generation weight-loss 10% medications 15% Total body weight loss Focus area and 20% high unmet need 25% 30% Bariatric surgery Content developed by Zealand Pharma. Segment characteristics and drivers Payer-reimbursed segment (prescriber-driven) Key drivers ос . Relative weight loss • Comorbidity risk reduction Health outcomes data • Safety Tolerability Self-pay segment (consumer-driven) Key drivers Desired weight loss Quality of weight loss, incl. muscle preservation Tolerability Convenience and administration Patients' willingness-to-pay 0

View entire presentation